Coronavirus: EMA recommends COVID-19 Vaccine Janssen for authorisation in the EU
22. März 2021 – After a thorough evaluation, EMA’s human medicines committee (CHMP) concluded by consensus that the data on the vaccine were robust and met the criteria for efficacy, safety and quality. COVID-19 Vaccine Janssen is the fourth vaccine recommended in the EU for preventing COVID-19.
Results from a clinical trial involving over 44,000 people showed that the vaccine had a 67 % efficacy. The side effects with COVID-19 Vaccine Janssen in the study were usually mild or moderate and cleared within a couple of days after vaccination.
For more information, see here.